Aquestive Therapeutics — Third Quarter 2026 Earnings Summary

Aquestive Therapeutics resubmitted its New Drug Application for Anaphylm, an oral epinephrine product for treating anaphylaxis, with the FDA assigning a PDUFA goal date of March 16, 2027. The company reported third-quarter 2026 total revenues of $7.6 million, a 41% decrease from the prior year period, driven primarily by fluctuations in Suboxone product orders. Net loss for the quarter was $16.5 million, while cash and cash equivalents stood at $90.3 million as of September 30, 2026. Additionally, Aquestive granted Eton Pharmaceuticals exclusive U.S. commercialization rights to Libervant in exchange for a $10 million upfront payment and potential milestone payments.